NICE trials a faster route for promising medicines into NHS managed access
NICE and NHS England are testing a streamlined pathway that could move selected medicines into NHS managed access with less delay than the current system allows. The new model, called the Streamlined Managed Access Route for Therapies or SMART, is built around a simple tension in modern health policy: patients should not wait unnecessarily for promising treatments, yet public funding still depends on evidence strong enough to justify routine NHS use.
The pilot does not abandon NICE’s evidence standards. It changes the timing and structure of the review.
Under the existing approach, medicines that enter managed access are assessed twice by NICE, first before access begins and then again after more evidence has been collected. SMART would compress that front-end process by using a shorter initial assessment to decide whether a medicine is suitable for managed access, followed later by a full NICE evaluation once more real-world evidence is available. In practical terms, that means some treatments could reach patients while the system continues to learn how they perform outside the trial setting.
A shorter initial assessment, then a full review later
The central aim of the pilot is speed. NICE and NHS England hope the pathway could shorten the time it takes for suitable medicines to enter managed access from around a year to as little as six months. The wording matters here: this is an objective of the pilot, not a guaranteed delivery date. The real test is whether the process can move faster without weakening the decisions that protect patients, the NHS budget, and confidence in the appraisal system.
That balance is easiest to understand in therapies where the early signal looks promising but the evidence base is still incomplete. Some medicines may show enough potential to justify early use, especially when the unmet need is high and the route to collecting additional data is clear. A managed access pathway creates a controlled bridge between clinical hope and reimbursement certainty. It allows the NHS to use the treatment while the evidence matures, rather than forcing a binary choice between immediate adoption and long delay.
Which medicines are eligible for the pilot
The pilot is designed for medicines that appear promising, can be introduced into the NHS relatively quickly, and come with clear plans for gathering further evidence. They also have to represent good value for money for the NHS. Those criteria are doing a lot of work. They narrow the candidate pool to therapies where the likely benefit, implementation feasibility, and economic case are all plausible enough to justify a streamlined process.
In other words, SMART is not an open door for any new product that arrives with enthusiasm attached. It is a targeted pathway for medicines that already have a credible case and a practical roadmap for learning more once they are in use. The evidence collection plan is not a side detail; it is part of the therapy’s eligibility for the route.
Why managed access still depends on evidence quality
A faster pathway can only work if the subsequent evidence is usable. NICE’s independent committees will still conduct a full evaluation before any decision is made on long-term NHS use. That means the later review remains the decisive checkpoint, and the pilot preserves the same basic principle that has always governed NICE appraisals: access should reflect both clinical benefit and value for money.
Financial safeguards are built into the pilot to protect both the NHS and companies while additional evidence is being gathered. Those safeguards matter because managed access often sits in a difficult middle ground. A treatment may be too uncertain for routine commissioning today, yet too promising to hold back completely. Without safeguards, that middle ground can become unstable for commissioners and manufacturers alike. With them, the system can keep patients on treatment while limiting the financial and evidentiary risks that come with provisional access.
One sentence captures the policy shift plainly: the NHS wants earlier access without giving up the discipline of later proof.
What NICE and NHS England are trying to learn
The pilot is not just a test of speed. It is also a test of whether the pathway can be simpler and more efficient for everyone involved while remaining fair, transparent, and evidence-based. That goal reaches beyond administrative convenience. If the process works, it could reduce friction for companies developing therapies with strong early signals and for patients who would otherwise wait through prolonged assessment cycles before any NHS access is possible.
The deeper policy question is whether the streamlined model can preserve confidence in the eventual NHS decision. Faster access is attractive only if the later appraisal still has enough robust information to distinguish true clinical value from early optimism. A managed access model can help when uncertainty is temporary and measurable. It is much less useful when the evidence gaps are structural or when there is no realistic plan to close them.
Seen that way, SMART is an experiment in governance as much as in reimbursement. NICE and NHS England are testing whether the system can reduce the interval between promise and access while keeping the final judgment tied to hard evidence. The pilot will show whether that shorter first step can be made reliable enough to avoid becoming just another fast lane to uncertainty.
For now, the most concrete outcome is simply that the agency is trying to change the sequence of evaluation. A shorter initial review, an evidence-gathering period in the middle, and a full NICE appraisal at the end could become a workable model for selected therapies. The unresolved issue is whether the pathway will consistently deliver enough real-world data, fast enough, to support the kind of decisions that managed access is supposed to enable.